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Abstract
Low-molecular-weight heparins (LMWHs) are carbohydrate-based anticoagulants clinically used 
to treat thrombotic disorders, but impurities, structural heterogeneity or functional irreversibility 
can limit treatment options. We report a series of synthetic LMWHs prepared by cost-effective 
chemoenzymatic methods. The high activity of one defined synthetic LMWH against human 
factor Xa (FXa) was reversible in vitro and in vivo using protamine, demonstrating that 
synthetically accessible constructs can have a critical role in the next generation of LMWHs.
Heparin is a widely used anticoagulant to prevent and treat arterial and venous thrombosis1. 
There are three US Food and Drug Administration (FDA)-approved forms of heparin: 
unfractionated heparin (UFH, average molecular weight (MWavg) ~14,000 Da), LMWH 
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(MWavg 3,500–6,000 Da) and fondaparinux (MW 1,508 Da). UFH is rapid-onset, safe for 
renal-impaired patients and its effects can be reversed using the cationic-peptide drug 
protamine2; however, it shows a 1–6% incidence of heparin-induced thrombocytopenia 
(HIT), a life-threatening complication3. Introduced in the 1990s4, LMWHs are 
subcutaneously administered and have a longer half-life than UFH, permitting their 
outpatient use and self-administration. Due to these advantages, LMWH is the most widely 
prescribed heparin in the US5. However, LMWH can be used in renal-impaired patients only 
at reduced doses6 and is incompletely neutralized with protamine, thereby increasing the 
risks of bleeding. Fondaparinux, a synthetic pentasaccharide, is subcutaneously bioavailable 
and has reduced risks of HIT and osteoporosis7. However, it is primarily excreted through 
the kidney and thus is not suitable for renal-impaired patients6, and it lacks an antidote. The 
US FDA recently approved generic forms of LMWH and fondaparinux, underscoring the 
rapid growth in heparin-based drugs.
Heparin consists of a disaccharide repeating unit of either iduronic acid (IdoA) or glucuronic 
acid (GlcA) and glucosamine (GlcN) residues, each capable of carrying sulfate groups. The 
locations of sulfate groups on IdoA and GlcA dictate the anticoagulant activity of heparin8. 
In vivo, heparin is synthesized by a series of heparan sulfate (HS) biosynthetic enzymes 
(Supplementary Results, Supplementary Fig. 1). Recombinant HS biosynthetic enzymes, 
expressed in Escherichia coli, show comparable substrate specificities to their mammalian 
counterparts9. These recombinant enzymes offer a strategy to synthesize heparin 
oligosaccharides using a chemoenzymatic approach10–12.
LMWH is a depolymerized derivative of heparin, isolated from porcine intestine. A 
worldwide contamination of heparin in 2007 affected the purity and safety of LMWHs13 and 
was associated with over 200 deaths in the US14. This crisis revealed the fragility of the 
LMWH supply chain. The cost-effective preparation of a synthetic LMWH could improve 
drug safety and efficacy15. Currently available LMWHs are complex mixtures, having 
average molecular masses of 3,500–6,000 Da, corresponding to 12–20 saccharide units. 
Until now, the preparation of a homogeneous LMWH has not been possible owing to 
difficulties in the chemical synthesis. Thus, we sought to design and synthesize a potential 
lead compound for a new generation of LMWH, particularly to explore reversibility of 
treatment.
Five synthetic LMWHs (1–5, Fig. 1a and Supplementary Table 1), ranging from 
hexasaccharide to dodecasaccharide, were synthesized (Supplementary Note). The structures 
of 1–4 contain a different number of IdoA2S-GlcNS6S (where S is sulfate) repeating units 
near their reducing ends. Synthetic LMWH 5 differs from 4, as it has two 3-O-sulfate groups 
(Fig. 1). The synthesis of 1 was initiated from a commercially available monosaccharide, 1-
O-(para-nitrophenyl)-glucuronide (GlcA-pNP) (Supplementary Fig. 2). Elongation of GlcA-
pNP to a hexasaccharide used two bacterial glycosyltransferases: KfiA (N-
acetylglucosaminyl transferase from E. coli K5 strain) and PmHS2 (heparosan synthase 2 
from Pasteurella multocida). N- and O-sulfation and epimerization produced 1 (ref. 12), 
which was expected to have a comparable pharmacological profile to that of fondaparinux, 
as both have very similar structures. The approach also produced hexasaccharide 6 (461 mg, 
Supplementary Table 2), an intermediate for subsequent syntheses.
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The syntheses of 2, 3 and 4 were initiated from hexasaccharide 6 through intermediates 7, 8 
and 9, respectively (Fig. 1b and Supplementary Table 1). These intermediates contain 
multiple IdoA2S-GlcNS repeating units, posing a synthetic challenge owing to the substrate 
specificity of C5-epimerase (C5-epi). A carefully designed sequence of enzymatic steps was 
used for high purity and yields. The conversion of GlcA to IdoA2S involves two steps: C5-
epi catalyzes epimerization of a GlcA to an IdoA, and 2-O-sulfotransferase (2-OST) 
transfers a sulfate group to IdoA. C5-epi catalyzes both the forward and reverse reactions, 
leading to the incomplete conversion of GlcA to IdoA2S16 and a complex mixture of 
products17. The placement of a pentasaccharide domain, GlcN-trifluoroacetyl(TFA)-GlcA-
GlcNS-GlcA-GlcNS, into the substrate directs C5-epi to irreversibly react with only the 
GlcA residue flanked with two GlcNS residues and avoids incomplete conversion.
The conversion of 6 to 7 to construct the pentasaccharide domain recognized by C5-epi was 
completed in four steps. The GlcNTFA residue (residue A) of hexasaccharide 6 was first 
converted to a GlcNS residue (step a, Fig. 1b). The resultant hexasaccharide was then 
elongated to an octasaccharide in two enzymatic steps (steps b and c, Fig. 1b), to obtain the 
desired pentasaccharide domain (dashed box, Fig. 1b). The conversion of GlcA (residue E) 
to IdoA2S in 7 was achieved by C5-epi and 2-OST (step d, Fig. 1b). The formation of the 
IdoA2S residue removes its reactivity toward further C5-epi modification. Repeating these 
steps (steps a–d, Fig. 1b) once or twice produced 8 and 9, respectively. The syntheses of 7, 8 
and 9 were completed (Supplementary Table 2), and structural characterization and purity 
are shown in Supplementary Figures 22–33. The octasaccharide 7 and decasaccharide 8 
were converted to 2 and 3, respectively, after N-sulfation, 6-O-sulfation and 3-O-sulfation; 
dodecasaccharide 9 was converted to 4 after 6-O-sulfation and 3-O-sulfation. The 
conversion of 4 to 5 was achieved by 3-O-sulfotransferase isoform 5 (3-OST-5) 
modification (Fig. 1b). Final-product purity was confirmed by HPLC. Structures were 
determined by MS and NMR analyses (Supplementary Figs. 4–19) and MS-assisted 
sequence analysis18 (Supplementary Figs. 20 and 21).
A clinical benefit of UFH and some LMWH chains is their ability to be cleared from the 
circulation through the liver, allowing these agents to be used in patients with renal 
impairment. We examined whether the synthetic LMWHs showed similar clearance profiles. 
UFH and larger chains in LMWH are known to bind to Stabilin-2, a scavenger receptor 
present on liver sinusoidal endothelial cells that mediates their clearance19. Like UFH and 
the LMWH enoxaparin, 3, 4 and 5 showed significant (P < 0.0001) endocytosis in cells 
stably transfected with Stabilin-2, whereas 1 and 2 showed very low internalization 
(Supplementary Fig. 34). Using a mouse model, we compared the retention of synthetic 
LMWHs in the liver with that of UFH and enoxaparin (Fig. 2a). Larger constructs (3, 4 and 
5) were retained in the liver, whereas smaller-size constructs (1 and 2) showed a very low 
level of liver retention (Fig. 2a).
We determined the anticoagulant activities of the synthetic LMWHs. All compounds (1–5) 
showed strong antithrombin (AT)-binding affinity (Kd 5–30 nM) (Supplementary Table 1). 
Results of anti-FXa activity assays showed lower half-maximal inhibitory concentration 
(IC50) values for 1–5 than UFH and enoxaparin, confirming their potent anti-FXa activity 
(Supplementary Fig. 35). Unlike UFH and enoxaparin, synthetic LMWHs have no 
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detectable anti-factor IIa (FIIa) activity, and, thus, these compounds are FXa-specific 
inhibitors. Our data also suggest that compounds larger than dodecasaccharides are required 
for anti-FIIa activity. Bemiparin, a ‘second-generation’ LMWH, was recently approved by 
the European Medicines Agency (EMA). It has considerably lower anti-FIIa activity than 
other LMWH drugs but similar clinical utility, suggesting that anti-FIIa activity is not 
critical20.
We next determined the protamine reversibility of the anticoagulant activity of five synthetic 
LMWHs (Fig. 2b). In contrast to the activities of 1–3, the activity of 4 was partially reversed 
by protamine and the activity of 5 was more reversible than enoxaparin and showed the 
same protamine reversibility as UFH activity (Fig. 2b). Using an ex vivo mouse model, we 
confirmed that 5 has similar sensitivity to protamine neutralization as UFH. As expected, 
enoxaparin was only partially neutralized by protamine (Fig. 2c). Finally, using a mouse-
tail-clip bleeding model, we demonstrated that protamine shortened the prolongation of 
bleeding time induced by 5 (Fig. 2d), confirming the sensitivity of 5 to protamine 
neutralization in vivo. The US FDA has recently approved three new anticoagulants—
dabigatran etexilate, rivaroxaban and apixaban—however, none of these drugs has an 
antidote. Although other strategies to inhibit anticoagulant drugs using an engineered FXa-
like protein21 or antithrombin mutant22 have been reported, these methods remain to be 
approved by a regulatory agency. Synthetic LMWH 5 can be neutralized by protamine, an 
FDA-approved antidote for UFH.
The superb sensitivity toward protamine neutralization shown by 5 suggests that both 
sulfation pattern and size contribute to its sensitivity to neutralization. Currently marketed 
LMWHs, for example, enoxaparin, are a mixture of oligosaccharides with a broad size 
distribution of chains, having different affinities toward protamine. Our data suggest that 
protamine only neutralizes chains in LMWHs that are larger than decasaccharides. Smaller 
chains, pentasaccharide to decasaccharide, can have anticoagulant activity23, even though 
they are not protamine reversible. Consequently, only partial neutralization for commercial 
LMWH can be achieved with protamine. Synthetic LMWH 5 has a uniformly high affinity 
to protamine because it is a structurally homogeneous compound. In addition, our results 
demonstrate that an extra 3-O-sulfate group increases the sensitivity for protamine 
neutralization, suggesting that the sulfation pattern has a critical role in protamine binding.
Additional efforts are necessary to further develop 5 into an LMWH drug candidate. First, 
replacement of pNP aglycone should eliminate concerns that it might be converted to p-
nitrophenol in vivo, leading to a potentially harmful metabolite (http://www.epa.gov/
ttnatw01/hlthef/nitrophe.html). Second, a comprehensive structure-activity relationship 
study will be required to understand the contribution of sulfation pattern to the 
pharmacological effects.
LMWHs are critical for the practice of modern medicine, yet their production still depends 
on a long supply chain that is vulnerable to contamination and adulteration. After the 
contamination crisis, the US FDA and EMA implemented a series of new approaches to 
monitor the purity of heparin drugs. Although these efforts have stopped the influx of 
contaminated heparin into the market, a long-term solution should be to manufacture 
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synthetic heparin under highly regulated processes, eliminating the need for animal-sourced 
heparin4,15. Chemoenzymatic synthesis offers a promising approach toward this goal. A 
homogeneous product reduces the complexity for the quality control during the 
manufacturing process and is compatible with standard approval processes by regulatory 
agencies24. Although the structures produced through chemoenzymatic synthesis are limited 
by the substrate specificities of the enzymes, their synthetic capability can be expanded 
through better understanding of enzyme properties. As demonstrated in the present study, a 
firm understanding of C5-epi specificity resulted in the design of a modification sequence 
leading to the synthesis of the critical IdoA2S-GlcNS repeating domain. The next challenge 
will be to determine whether a large-scale synthesis of homogeneous LMWH can be 
accomplished to meet the needs of the anticoagulant drug market. The synthesis of 5 
requires 22 synthetic steps, but it is much shorter than the synthesis of fondaparinux, which 
requires 50 steps25. Fondaparinux is now synthesized in kilogram scale and has been a 
profitable drug for ten years, suggesting that further development of the chemoenzymatic 
approach will result in cost-effective products, accelerating the modernization of LMWH 
therapeutics.
Methods
Methods and any associated references are available in the online version of the paper.
ONLINE METHODS
Determination of the in vitro and ex vivo anti-FXa activity
Assays were based on a previously published method26,27. Briefly, human factor Xa (FXa) 
(Enzyme Research Laboratories) was diluted to 50 U ml−1 with PBS. The chromogenic 
substrate S-2765 was from Diapharma and made up at 1 mg ml−1 in water. UFH (from US 
Pharmacopeia), enoxaparin (Lovenox from local pharmacy) and synthetic 1 to 5 were 
dissolved in PBS at various concentrations (3–600 μg ml−1). The reaction mixture, which 
consisted of 20 μl of human plasma (Sigma-Aldrich) and 8 μl of the solution containing the 
sample, was incubated at room temperature for 5 min. Factor Xa (100 μl) was then added. 
After incubation at room temperature for 4 min, 30 μl of S-2765 substrate was added. The 
absorbance of the reaction mixture was measured at 405 nm continuously for 5 min. The 
absorbance values were plotted against the reaction time to measure the reaction rate. The 
initial reaction rates were used to measure the activity of FXa.
Preparation of 35S-labeled LMWHs
UFH (from US Pharmacopeia) and enoxaparin (from local pharmacy) were modified by 
NST. The reaction consisted of MES (2-(N-morpholino)ethanesulfonic acid, Sigma) 50 mM 
pH 7.0, NST 0.1 mg ml−1 and 0.5 nmol [35S]PAPS (specificity activity of [35S]PAPS was 
2.2 × 104 cpm pmol−1), 50 μg of UFH or enoxaparin in total 500 μl at 37 °C overnight. The 
products were purified by a diethylaminoethyl (DEAE) column. 35S-labeled synthetic 1 to 4 
were prepared from the synthetic LMWH constructs intermediates without 3-O-sulfate 
groups. The reaction consisted of MES 50 mM pH 7.0, 10 mM MnCl2, 5 mM MgCl2, 3-
OST-1 0.1 mg ml−1 and 0.5 nmol [35S]PAPS and oligosaccharide (5 μg) in total 500 μl at 37 
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°C overnight. 35S-labeled synthetic 5 was prepared from synthetic 4. The reaction consisted 
of MES 50 mM pH 7.0, 10 mM MnCl2, 5 mM MgCl2, 3-OST-5 0.1mg ml−1 and 0.5 nmol 
[35S] PAPS and 4 (5 μg) in total 500 μl at 37 °C overnight. The 35S-labeled 5 was purified 
by a DEAE-HPLC column.
Determination of the binding affinity of synthetic LMWHs to antithrombin (AT)
The dissociation constant (Kd) of each sample and AT was determined using affinity co-
electrophoresis28. Approximately 1,500–2,500 c.p.m. of 35S-labeled synthetic 1 to 5 was 
loaded per lane with zones of AT at concentrations 0, 8, 16, 32, 60, 120, 250, 500 and 1,000 
nM. The gel was performed at 300 mA for 2 h, dried and analyzed on a PhosphoImager 
(Amersham Biosciences, Storm 860). The retardation coefficient was calculated at R = 
(M0−M)/M0, where M0 is the mobility of the polysaccharide through the zone without AT, 
and M is the mobility of the sample through each separation zone. The retardation 
coefficient was then plotted against the retardation coefficient divided by its respective 
concentration of AT. The slope of the line represents −1/Kd.
HPLC analysis
Both DEAE-HPLC and polyamine-based anion exchange (PAMN)-HPLC were used to 
analyze the purity of the products. The elution conditions for the HPLC analysis were 
described elsewhere29. Briefly, for DEAE-HPLC method, the DEAE-NPR column 
(Tosohaas) was eluted with a linear gradient of NaCl in 20 mM sodium acetate buffer (pH 
5.0) from 0 to 1 M in 60 min at a flow rate of 0.4 ml min−1. For PAMN-HPLC, the column 
(Waters) was eluted with a linear gradient of KH2PO4 from 0 to 1 M in 40 min at a flow rate 
of 0.5 ml min−1.
Neutralization of synthetic LMWHs by protamine in vitro
The procedures followed those reported in a previous publication30. The synthetic LMWH 
constructs and protamine chloride (Sigma-Aldrich) were dissolved in PBS. The 
concentrations of the synthetic LMWH samples for each construct were different because 
each sample had different IC50 values for the anti-FXa activity. Generally, the final 
concentration of each test compound was about four times its IC50 value. The reaction 
mixture consisted of 20 μl of human plasma (Sigma-Aldrich), 2 μl of stock solutions of 
synthetic LMWHs and 8 μl of protamine with various concentrations (0–90 μg ml−1), and 
was incubated at room temperature for 5 min. The concentrations of 1, 2, 3, 4 and 5 stocks 
were 4.4 μg ml−1, 5.4 μg ml−1, 4.7 μg ml−1, 5.7 μg ml−1 and 6.6 μg ml−1, respectively. The 
concentrations of enoxaparin and UFH stocks, two control samples, were 126 μg ml−1 and 
21 μg ml−1, respectively. The mixture (30 μl) was then subjected to anti-FXa activity 
measurement as described above.
Neutralization of synthetic LMWHs by protamine in mice
The study was performed on 8-week-old male C57BL/6J mice (Jackson Laboratories, Bar 
Harbor, ME) (n = 4 per group). The mouse experiments were approved by the University of 
North Carolina Animal Care and Use Committees and complied with US National Institutes 
of Health guidelines. Under isoflurane anesthesia, mice were subcutaneously administered 
Xu et al. Page 6













with PBS, UFH (3 mg kg−1), enoxaparin (3 mg kg−1) or 5 (0.6 mg kg−1) 30 min before a 
protamine administration. Protamine (15 mg kg−1) or PBS was administered intravenously 
via retro-orbital plexus injection, and 5 min later, blood samples were drawn from the 
inferior vena cava into syringes preloaded with 3.2% solution of sodium citrate (final 
volume ratio 9:1). To obtain mouse plasma, blood samples were centrifuged at 4,000g for 15 
min at 4 °C. Mouse plasma was then used to determine anti-FXa activity. Ex vivo analysis of 
anti-FXa activity was done similarly to the in vitro study described above. Briefly, plasma 
(10 μl) from different groups of mice was incubated with 80 nM human factor Xa (10 μl) at 
room temperature for 4 min and S-2765 (1 mg ml−1, 30 μl) was then added. The anti-FXa 
activity in the mouse plasma from the PBS injected mice was defined as 100%. Statistical 
analysis for multiple comparisons was performed by two-way analysis of variance 
(ANOVA) with Bonferroni’s post hoc test (GraphPad Prism Software).
Mouse model of tail bleeding
Under isoflurane anesthesia, 8-week-old male C57BL/6J mice (n = 8 per group) were 
administered with PBS or 5 (0.6 mg kg−1) subcutaneously, and 30 min later PBS or 
protamine (15 mg kg−1) was administered via retro-orbital intravenous injection. After 5 
min the distal part of the tail was transected at the constant diameter (1.5 mm), 
approximately 3–4 mm from the end, resulting in both arterial and venous bleeding. The tail 
was immediately placed in a 15-ml Falcon tube containing 13 ml of pre-warmed PBS (37 
°C), and blood loss was observed for 30 min. The primary bleeding time was defined as the 
time to the first cessation of bleeding. Subsequently, time for each reinitiated bleeding was 
also recorded, and used to calculate total bleeding time. One mouse in 5/protamine group 
received an inaccurate protamine injection and was excluded from the study. The blood 
collected in PBS was used to calculate total blood volume loss. Formic acid was added to 
samples (70:30 ratio) and absorbance was measured at 405 nm. A standard curve was 
generated by mixing 13 ml of PBS with known amounts of blood. Statistical analysis 
between each group was performed by one-way ANOVA (GraphPad Prism Software) 
followed by Bonferroni’s multiple-comparison test.
MS analysis
The low-resolution MS analyses were performed on a Thermo LCQ-Deca. A syringe pump 
(Harvard Apparatus) was used to introduce the sample by direct infusion (35 μl min−1). 
Experiments were carried out in negative ionization mode. Synthetic nonsulfated 
oligosaccharides were diluted in 200 μl of H2O with the electrospray source set to 5 KV and 
275 °C. Sulfated LMWHs were diluted in 200 μl of 10 mM ammonium bicarbonate with the 
electrospray source set to 3 KV and 200 °C. Sulfated oligosaccharide (1 μl) was diluted in a 
different working solution containing 200 μl of 10 mM ammonium bicarbonate. 
Experiments for sulfated oligosaccharides were carried out in negative ionization mode with 
the electrospray source set to 2 KV and 200 °C. The automatic gain control was set to 1 × 
107 for full scan MS. The MS data were acquired and processed using Xcalibur 1.3.
High-resolution ESI-MS analysis was conducted on Thermo LTQ XL Orbitrap under the 
following conditions. A Luna hydrophilic liquid interaction chromatography (HILIC) 
column (2.0 × 150 mm2, 200 Å, Phenomenex) was used to separate the oligosaccharide 
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mixture. Mobile phase A was 5 mM ammonium acetate prepared with HPLC-grade water. 
Mobile phase B was 5 mM ammonium acetate prepared in 98% HPLC-grade acetonitrile 
with 2% of HPLC-grade water. After injection of 8.0 μl oligosaccharide mixture (1.0 μg 
μl−1) through an Agilent 1200 autosampler, an HPLC binary pump was used to deliver the 
gradient from 10% A to 35% A over 40 min at a flow rate of 150 μl min−1. The LC column 
was directly connected online to the standard electrospray ionization source of LTQ-
Orbitrap XL Fourier transform (FT) mass spectrometer (MS) (Thermo Fisher Scientific). 
The source parameters for FT-MS detection were optimized using fondaparinux to minimize 
the insource fragmentation and sulfate loss and maximize the signal-to-noise ratio in the 
negative-ion mode. The optimized parameters included a spray voltage of 4.2 kV, a capillary 
voltage of −40 V, a tube-lens voltage of −50 V, a capillary temperature of 275 °C, a sheath 
flow rate of 30 and an auxiliary gas flow rate of 6. External calibration of mass spectra 
routinely produced a mass accuracy of better than 3 ppm. All FT mass spectra were acquired 
at a resolution of 60,000 with 300–2,000 Da mass range.
NMR analysis
Synthetic LMWH constructs and intermediates were analyzed by 1D 1H-NMR and 2D 
NMR (1H-1H COSY, 1H-13C HMQC). All NMR experiments were performed at 298 K on 
Bruker Avance II 800 MHz spectrometer with Topsin 2.1 software. Samples (3.0 to 6.0 mg) 
were each dissolved in 0.5 ml D2O (99.996%, Sigma-Aldrich) and lyophilized three times to 
remove the exchangeable protons. The samples were re-dissolved in 0.4 ml D2O and 
transferred to NMR microtubes (O.D. 5 mm, Norrell). We carried out 1D 1H NMR 
experiments with 256 scans and an acquisition time of 850 ms. We carried out 2D 1H-1H 
COSY experiments with 16 scans, 1.5-s relaxation delay and 500-ms acquisition time. We 
carried out 2D 1H-13C HMQC experiments with 16 scans, 1.5-s relaxation delay and 250-m 
acquisition time.
The compounds were also analyzed by 1D 1H-NMR, 1D 13C-NMR and 2D NMR (1H-1H 
COSY, 1H-13C HSQC) on Varian Inova 500 MHz spectrometer with VnmrJ 2.2D software. 
Samples (2.0 to 5.0 mg) were dissolved in 0.5 ml D2O (99.994%, Sigma-Aldrich) and 
lyophilized three times to remove the exchangeable protons. The samples were re-dissolved 
in 0.5 ml D2O and transferred to NMR microtubes (OD 5 mm, Norrell). We carried out 
1D 1H-NMR experiments with 256 scans and an acquisition time of 768 ms; 1D 13C-NMR 
experiments with 40,000 scans, 1.0-s relaxation delay and an acquisition time of 1,000 ms; 
2D 1H-1H COSY experiments with 48 scans, 1.8-s relaxation delay and 204-ms acquisition 
time; and 2D 1H-13C HSQC experiments with 48 scans, 1.5-s relaxation delay and 256-ms 
acquisition time.
Determination of the binding of synthetic LMWHs to stabilin-2
The stabilin-2 cell line expressing the 190-HARE19,31, a truncated form of Stabilin-2, was 
grown to 90% confluency with DMEM + 8% FBS + 50 μg ml−1 hygromycin B in 24-well 
plates for at least 2 d before the experiment in a standard tissue-culture incubator. 
Endocytosis medium (DMEM + 0.05% BSA) containing a known amount of 35S-labeled 
synthetic LMWH construct, enoxaparin or UFH was added to each well in triplicate and 
allowed to incubate with the cells for 3 h at 37 °C, 5% CO2. The cells were then washed 
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with Hanks’ Balanced Salt Solution (1.26 mM CaCl2, 5.33 mM KCl, 0.44 mM KH2PO4, 0.5 
mM MgCl2, 0.41 mM MgSO4, 138 mM NaCl, 4.0 mM NaHCO3, 0.3 Na2HPO4, 0.3 mM 
phenol red, pH 7.2) three times, and cells were lysed in 0.4 ml 0.3 M NaOH. We mixed 0.35 
ml of the cell lysate mixture with 4 ml scintillation fluid (PerkinElmer) and measured 
radioactivity by a Beckman Coulter LS6500 scintillation counter. Receptor-specific 
internalization was assessed by incubating each radio labeled ligand with at least a 100-fold 
excess of unlabeled UFH17. The remaining 0.05 ml cell lysate was used to determine protein 
concentrations using the Bradford reagent (Sigma-Aldrich). Statistical analysis between 
each group was performed by one-way ANOVA (SigmaPlot Software, Systat).
Determination of the clearance of synthetic LMWHs in vivo
The mouse experiment was approved by the University of Nebraska Animal Care and Use 
Committees. Five- to six-week-old BALB/c male mice (Harlan Laboratories) weighing 18–
20 g were anesthetized in a small 34 °C chamber with a flow of oxygen containing 4% 
isoflurane. Once the mice were unconscious, they were individually placed on a heated pad 
with a nose cone fitted over their snout with a constant flow of oxygen containing 2% 
isoflurane. A specific amount of 35S-labeled synthetic LMWH construct, LMWH, or UFH 
was injected via the lateral tail vein using a 27G1/2 needle mounted on a 1-ml syringe. The 
labeled material was allowed to circulate in the blood for 12 min while the mouse lay 
unconscious. The abdominal cavity was exposed by incision and the liver was collected, 
washed and weighed. Approximately 100 mg from each of the lobes was homogenized in 
0.75 ml 1% NP-40 and then centrifuged at 12,000g for 2 min to pellet insoluble material. 
The supernatant was then added to 4 ml scintillation fluid, mixed for 30 min by rocking and 
then radioactivity was assessed by a Beckman Coulter LS6500 scintillation counter. The 
data is presented as the percentage of CPM in total liver divided by total CPM injected ± 
s.e.m. of 3–5 mice per ligand. Statistical analysis between each group was performed by 
one-way ANOVA (SigmaPlot Software, Systat) followed by Bonferroni’s post hoc 
comparison test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Targeted structures and schematic synthesis of synthetic LMWHs
(a) The five synthetic LMWHs prepared in this study. (b) Hexasaccharide 6 (Supplementary 
Fig. 2) was converted to octasaccharide 7, decasaccharide 8 and dodecasaccharide 9 to 
synthesize 2, 3 and 4, respectively. The conversion of 4 to 5 was achieved by 3-OST-5 
modification. The chemical reactions and yield at each step are presented in Supplementary 
Figure 3. abbreviations: NST, N-sulfotransferase; pmHS2, heparosan synthase 2 from P. 
multocida; KfiA, N-acetylglucosaminyl transferase from E. coli K5 strain; C5-epi, 
glucuronyl C5-epimerase; 2-OST, 2-O-sulfotransferase; 6-OSTs, 6-O-sulfotransferase 
isoform 1 and isoform 3; 3-OST-1, 3-O-sulfotransferase isoform 1; 3-OST-5, 3-O-
sulfotransferase isoform 5; NTFA, N-trifluoroacetyl; GlcNTFa, N-trifluoroacetylated 
glucosamine; GlcA, glucuronic acid; idoa2S, 2-O-sulfated iduronic acid; GlcNS, N-
sulfoglucosamine; GlcNAc, N-acetylated glucosamine.
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Figure 2. Determination of the clearance, anti-FXa activity and sensitivity to protamine 
neutralization of synthetic LMWHs
(a) percentage of 35S-labeled synthetic LMWHs that was retained in the liver in a mouse 
model. In comparison to synthetic 1, all tested compounds, with the exception of synthetic 2 
and enoxaparin, showed significantly higher retention in liver (****P < 0.0001). (b) FXa 
activity of synthetic LMWHs in the presence of different concentrations of protamine under 
in vitro conditions. (c) Ex vivo reversibility of anti-FXa activity by protamine. The inhibition 
of FXa activity by the test compounds was significantly affected in the presence of 
protamine (*P < 0.05 and ****P < 0.0001). Data presented in a–c are the average of three to 
five determinations ± s.d. (d) Effect of 5 and protamine on tail-bleeding time after tail 
transection. protamine significantly shortened the primary bleeding time (**P < 0.01) that 
was induced by 5. Each data point represents the measured value from an individual mouse 
in the test group. Data are presented as mean ± s.d. The blood loss and total bleeding time 
were also measured (Supplementary Fig. 36).
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